Publications by authors named "Simon Fricker"

Claim this Profile
S
Self-delivering RNAi immunotherapeutic PH-762 silences PD-1 to generate local and abscopal antitumor efficacy.
Benjamin Cuiffo, Melissa Maxwell, Dingxue Yan, Ramdane Guemiri, Andrew Boone, Simon P Fricker

Front Immunol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization and Validation of Antibodies for Immunohistochemical Staining of the Chemokine CXCL12.
Simon P Fricker, Kam Sprott, Melanie Spyra, Philipp Uhlig, Nicole Lange

J Histochem Cytochem· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting chemokine receptors for HIV: past, present and future.
Simon P Fricker

Future Med Chem· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Specificity for a CCR5 Inhibitor Is Conferred by a Single Amino Acid Residue: ROLE OF ILE198.
Gloria Lau, Jean Labrecque, Markus Metz, Roy Vaz, Simon P Fricker

J Biol Chem· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemokine receptor modeling: an interdisciplinary approach to drug design.
Simon P Fricker, Markus Metz

Future Med Chem· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of substituted imidazolidinylpiperidinylbenzoic acids as chemokine receptor 5 antagonists: potent inhibitors of R5 HIV-1 replication.
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Ernest McEachern, Simon Fricker

J Med Chem· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiology and pharmacology of plerixafor.
Simon P Fricker

Transfus Med Hemother· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication.
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Ernest McEachern, Simon Fricker

ACS Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Renee M Mosi, Virginia Anastassova, Jennifer Cox, Marilyn C Darkes, Stefan R Idzan, Simon P Fricker

Biochem Pharmacol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies for the biological evaluation of gold anticancer agents.
Simon P Fricker

Anticancer Agents Med Chem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Ernest McEachern, Simon Fricker

Bioorg Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.
Markus Metz, Elyse Bourque, Jean Labrecque, Sanjay J Danthi, Jonathan Langille, Simon P Fricker

J Am Chem Soc· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor actions of ruthenium(III)-based nitric oxide scavengers and nitric oxide synthase inhibitors.
Frederick W Flitney, Rebecca J Pritchard, Gordon D Kennovin, Stuart K Bisland, David G Hirst, Simon P Fricker

Mol Cancer Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.
Jean Labrecque, Markus Metz, Gloria Lau, Marilyn C Darkes, Rebecca S Y Wong, Simon P Fricker

Virology· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity.
Yongbao Zhu, Beth R Cameron, Renee Mosi, Virginia Anastassov, Jennifer Cox, Simon P Fricker

J Inorg Biochem· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication.
Renato Skerlj, Gary Bridger, Yuanxi Zhou, Elyse Bourque, Jonathan Langille, Simon Fricker

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR4 in clinical hematology.
Gary Calandra, Gary Bridger, Simon Fricker

Curr Top Microbiol Immunol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCL12 (SDF-1)/CXCR4 pathway in cancer.
Beverly A Teicher, Simon P Fricker

Clin Cancer Res· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cysteine proteases as targets for metal-based drugs.
Simon P Fricker

Metallomics· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier.
Monica S Thakar, Erlinda B Santos, Simon Fricker, Gary Bridger, Rainer Storb

Blood· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Veronique Bodart, Virginia Anastassov, Marilyn C Darkes, Stefan R Idzan, Jean Labrecque, Simon P Fricker

Biochem Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A time-resolved fluorescent lanthanide (Eu)-GTP binding assay for chemokine receptors as targets in drug discovery.
Jean Labrecque, Rebecca S Y Wong, Simon P Fricker

Methods Mol Biol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokines & inflammation--GTCbio's seventh annual conference. 29-30 January 2009, San Diego, CA, USA.
Simon Fricker

IDrugs· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
Rebecca S Y Wong, Veronique Bodart, Markus Metz, Jean Labrecque, Gary Bridger, Simon P Fricker

Mol Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel CXCR4 antagonist for hematopoietic stem cell mobilization.
Simon P Fricker

Expert Opin Investig Drugs· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis